COVID

Rhetoric first, action later: the G7 approach to global equity

Mon, 02/22/2021 - 22:46
The G7 countries met (virtually) on Friday, February 19, to share variants of “no one is safe until everyone is safe” and discuss the importance of global equity of Covid-19 vaccines and the need for international cooperation. (Sound familiar? That’s because we heard the same things from the G20 in November.) 

Vaccine hesitancy will soon become the primary obstacle to global immunity

Tue, 02/16/2021 - 01:00
Global manufacturing capacity has been the primary rate limiter for Covid-19 vaccinations. Our vaccine manufacturing infrastructure was not designed to produce enough doses to cover 70% of the world’s population within a year (in addition to regular and routine vaccines) and, as expected, demand is outstripping supply. There has been good news on the manufacturing front, however, with several large pharma companies recently joining with rivals to ramp up production.

COVAX released draft allocations for the first half of 2021

Mon, 02/08/2021 - 13:00
The COVAX partnership released last week its first estimates of dose allocations for participating countries, covering planned deliveries from February through June. These are labeled as “indicative,” meaning the estimates are non-binding and subject to a list of caveats provided in both the distribution forecast and the supply update released in January. In fact, the language surrounding both documents seems on balance to contain more hedging than forecasting.

What is at Stake in EU’s Move to Control Vaccine Exports

Mon, 02/01/2021 - 13:00
AstraZeneca recently alerted the EU that it would only be able to deliver 25% of the 80-100 million doses of Covid-19 vaccine expected this quarter, due to production problems in the European plants. Under new export controls, EU member states can now block exports of Covid-19 vaccines if they believe that the vaccine producers are in danger of not meeting their supply contracts with the EU.

The US formally joined COVAX. Will it Matter?

Mon, 01/25/2021 - 13:00
Dr. Anthony Fauci, newly named the US Chief Medical Advisor, warmly addressed the WHO executive board within the first 24 hours of the Biden administration. Dr. Fauci confirmed that under President Joe Biden, the US will rejoin the WHO and will also join COVAX, the global mechanism designed to ensure equitable allocation of vaccines across the world.

Direct COVID vaccine deals by poorer countries are an important and encouraging development

Tue, 01/19/2021 - 13:00
This past week, we saw the first direct vaccine purchases made for low-income countries with the African Union’s purchase of 270 million doses of Covid-19 vaccines from Pfizer-BioNTech, OxfordAstraZeneca, and Johnson & Johnson (J&J). Though it is a relatively modest purchase, it represents a significant shift in the global power dynamics of the Covid-19 response.

Changing how India's vaccine numbers are represented in our data

Mon, 01/11/2021 - 13:00
The Serum Institute of India (SII), one of the world’s largest vaccine manufacturers, has publicly committed that half of the Covid-19 vaccines they produce will stay in India to serve the domestic market, while the remainder will be shipped out to other countries. This week, we have changed the way that India’s reserved doses of vaccine are represented in our data.

Tracking COVID vaccine regulatory approvals around the world

Fri, 12/18/2020 - 13:00
We have seen a lot of movement in regulatory approval of Covid-19 vaccines over the past two weeks, as vaccination campaigns begin to roll out. When tracking the Covid-19 vaccine landscape, it is important to keep in mind the difference between emergency use authorization and full authorization. Most Covid-19 vaccine approvals received thus far have been limited to emergency use.

What are the latest developments with vaccines developed in Russia and China?

Mon, 12/14/2020 - 13:00
We are frequently asked why some data about vaccines purchased by Russia and China appear to be missing from our data. The answer is because both countries control largely state-owned vaccine development and manufacturing chains, and, in part because of this, are notably less transparent than some other countries about advance purchases for domestic use as well as exports.